Medy-Tox Inc. (KOSDAQ:086900)

South Korea · Delayed Price · Currency is KRW

84,500

+10,500 (14.19%)

Jun 29, 2026, 3:30 PM KST

-48.13% (1Y)

Market Cap	553.91B -53.1%
Revenue (ttm)	244.02B +2.5%
Net Income	19.61B -7.4%
EPS	3,271.97 +6.3%
Shares Out	6.56M
PE Ratio	25.83
Forward PE	18.37
Dividend	1,200.00 (1.62%)
Ex-Dividend Date	Sep 29, 2025

Volume	61,449
Open	74,000
Previous Close	74,000
Day's Range	74,000 - 84,500
52-Week Range	73,400 - 179,800
Beta	0.41
Analysts	Hold
Price Target	124,750.00 (+47.63%)
Earnings Date	Aug 13, 2026

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 689

Stock Exchange KOSDAQ

Ticker Symbol 086900

Full Company Profile

Financial Performance

In 2025, Medy-Tox's revenue was 247.29 billion, an increase of 8.17% compared to the previous year's 228.62 billion. Earnings were 15.62 billion, a decrease of -2.26%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 086900 stock is "Hold." The 12-month stock price target is ₩124,750, which is an increase of 47.63% from the latest price.

Price Target

₩124,750

(47.63% upside)

Analyst Consensus: Hold

Stock Forecasts